A share price of Biocryst Pharmaceuticals Inc [BCRX] is currently trading at $7.24, down -0.96%. An important factor to consider is whether the stock is rising or falling in short-term value. The BCRX shares have gain 3.65% over the last week, with a monthly amount drifted -4.11%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Evercore ISI downgraded its rating to In-line on October 01, 2025, and kept the price target unchanged to $8. On April 29, 2025, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $20 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $15 on February 25, 2025. RBC Capital Mkts upgraded its rating to Outperform for this stock on September 18, 2023, and upped its price target to $10. In a note dated August 04, 2023, Jefferies upgraded an Buy rating on this stock but restated the target price of $11.
Biocryst Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $6.00 and $11.31. Currently, Wall Street analysts expect the stock to reach $12.67 within the next 12 months. Biocryst Pharmaceuticals Inc [NASDAQ: BCRX] shares were valued at $7.24 at the most recent close of the market. An investor can expect a potential return of 75.0% based on the average BCRX price forecast.
Analyzing the BCRX fundamentals
Trailing Twelve Months sales for Biocryst Pharmaceuticals Inc [NASDAQ:BCRX] were 557.51M which represents 49.41% growth. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at 0.1%, Pretax Profit Margin comes in at -0.06%, and Net Profit Margin reading is -0.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is 0.08 and Total Capital is 0.19. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.75.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.16 points at the first support level, and at 7.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.32, and for the 2nd resistance point, it is at 7.41.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Biocryst Pharmaceuticals Inc [NASDAQ:BCRX] is 2.25. On the other hand, the Quick Ratio is 2.22, and the Cash Ratio is 0.5. Considering the valuation of this stock, the price to sales ratio is 2.73.
Transactions by insiders
Recent insider trading involved HEGGIE THERESA, Director, that happened on Aug 13 ’25 when 70000.0 shares were sold. Director, HEGGIE THERESA completed a deal on Aug 13 ’25 to buy 70000.0 shares. Meanwhile, Director Hutson Nancy J sold 7000.0 shares on Dec 13 ’24.
